Product image of Montelukast Teva (Montelukast) supplied by GNH India

Montelukast Teva

Active Ingredient:
Montelukast
Origin:
EU

Montelukast Teva (Montelukast)

Montelukast, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma and allergic rhinitis by reducing inflammation and bronchoconstriction in patients who require long‑term control.

GNH India supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Teva B.V

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Montelukast acts on the leukotriene pathway to control chronic respiratory and allergic conditions.

  • Asthma: reduces the frequency of asthma exacerbations and improves lung function in persistent asthma.
  • Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis.
  • Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after vigorous physical activity.

How It Works

  • Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes from binding and triggering bronchoconstriction, mucus secretion, and airway inflammation. By inhibiting this pathway, the drug reduces airway hyper‑responsiveness and the inflammatory response that underlies asthma and allergic rhinitis.

Side Effects

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Headache: mild to moderate pain often reported during early treatment.
  • Abdominal pain: discomfort or cramping in the stomach region.
  • Cough: transient irritation of the airway.
  • Dyspepsia: indigestion or feeling of fullness.
  • Nasopharyngitis: mild upper‑respiratory tract infection symptoms.
  • Fatigue: occasional tiredness or lack of energy.

Serious or Rare Side Effects

  • Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention.
  • Angioedema: rapid swelling of the face, lips, tongue or throat.
  • Hepatic injury: abnormal liver function tests or jaundice.
  • Neuropsychiatric events: agitation, depression, or suicidal thoughts.
  • Anaphylaxis: rare systemic allergic reaction.
  • Blood dyscrasias: uncommon blood cell abnormalities.

Precautions & Warnings

Before initiating therapy, consider the following safety points.

  • Monitor liver function: periodic testing is advised for patients with pre‑existing hepatic disease.
  • Psychiatric history: use with caution in individuals with depression or suicidal ideation.
  • Acute asthma attacks: not a rescue medication; patients should retain a fast‑acting bronchodilator.
  • Hypersensitivity: discontinue if signs of allergic reaction appear.
  • Drug interactions: review concomitant medications for potential CYP450 effects.
  • Store below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Montelukast may interact with several drug classes; clinical judgment is required.

Major Interactions (Avoid)

  • Phenobarbital: induces metabolism, reducing montelukast exposure.
  • Rifampin: strong CYP3A4 inducer that may lower therapeutic levels.
  • Ketoconazole: potent CYP3A4 inhibitor, potentially increasing montelukast concentrations.

Moderate Interactions (Monitor Closely)

  • Zafirlukast or other leukotriene modifiers: additive risk of neuropsychiatric effects.
  • Warfarin: possible alteration of anticoagulant effect, monitor INR.
  • Oral contraceptives: may experience reduced efficacy; advise additional contraceptive measures.

Frequently Asked Questions

Montelukast Teva is prescribed to manage persistent asthma, relieve symptoms of allergic rhinitis, and prevent exercise‑induced bronchoconstriction. By targeting leukotriene‑mediated inflammation, it helps maintain airway openness and reduces allergic nasal symptoms.

Montelukast selectively blocks the CysLT1 receptor, which is activated by cysteinyl leukotrienes. This inhibition prevents leukotriene‑driven bronchoconstriction, mucus production, and airway inflammation, thereby improving breathing and reducing allergic nasal inflammation.

The appropriate dose of Montelukast Teva is determined by the prescribing clinician based on the patient’s age, weight, and specific condition. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for Montelukast in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus. Caution is also advised while breastfeeding, and a healthcare professional should be consulted.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids and long‑acting beta‑agonists. It is particularly useful for patients who prefer oral therapy or have difficulty using inhalers, but it is generally used as an add‑on rather than a sole rescue medication.

Montelukast Teva tablets should be stored below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Montelukast Teva is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events, though rare, include Stevens‑Johnson syndrome, angioedema, severe hepatic injury, and neuropsychiatric reactions such as depression or suicidal thoughts. Any sudden or severe symptoms should prompt immediate medical evaluation.

Montelukast Teva should be avoided in individuals with known hypersensitivity to montelukast or any component of the formulation. It is also not suitable as a rescue medication for acute asthma attacks and should be used with caution in patients with a history of psychiatric disorders.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Montelukast

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT